DarioHealth Corp. (DRIO)
USD 0.65
(-9.08%)
USD 0.65
(-9.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -59.42 Million USD | 11.79% |
| 2022 | -62.19 Million USD | 18.98% |
| 2021 | -76.76 Million USD | -164.81% |
| 2020 | -28.98 Million USD | -63.15% |
| 2019 | -17.76 Million USD | 0.2% |
| 2018 | -17.8 Million USD | -13.09% |
| 2017 | -15.74 Million USD | -44.6% |
| 2016 | -10.88 Million USD | -52.44% |
| 2015 | -7.14 Million USD | 44.54% |
| 2014 | -12.87 Million USD | 7.57% |
| 2013 | -13.93 Million USD | -144.99% |
| 2012 | -5.68 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.36 Million USD | 51.3% |
| 2024 Q1 | -6.91 Million USD | 42.36% |
| 2023 FY | -54.86 Million USD | 11.79% |
| 2023 Q3 | 16.9 Million USD | 201.92% |
| 2023 Q2 | -16.58 Million USD | -233.66% |
| 2023 Q4 | -12 Million USD | -170.99% |
| 2023 Q1 | 12.4 Million USD | 198.34% |
| 2022 Q4 | -12.61 Million USD | 24.41% |
| 2022 Q3 | -16.69 Million USD | 7.42% |
| 2022 Q2 | -18.02 Million USD | -12.96% |
| 2022 Q1 | -15.96 Million USD | 26.06% |
| 2022 FY | -62.19 Million USD | 18.98% |
| 2021 FY | -76.76 Million USD | -164.81% |
| 2021 Q1 | -14.96 Million USD | -66.34% |
| 2021 Q2 | -17.76 Million USD | -18.7% |
| 2021 Q3 | -22.44 Million USD | -26.34% |
| 2021 Q4 | -21.58 Million USD | 3.82% |
| 2020 FY | -28.98 Million USD | -63.15% |
| 2020 Q1 | -9.89 Million USD | -137.05% |
| 2020 Q2 | -4 Million USD | 59.5% |
| 2020 Q4 | -8.99 Million USD | -37.36% |
| 2020 Q3 | -6.55 Million USD | -63.5% |
| 2019 Q2 | -5.38 Million USD | -0.11% |
| 2019 Q4 | -4.17 Million USD | -48.77% |
| 2019 FY | -17.76 Million USD | 0.2% |
| 2019 Q1 | -5.37 Million USD | -7.89% |
| 2019 Q3 | -2.8 Million USD | 47.88% |
| 2018 Q4 | -4.98 Million USD | -22.64% |
| 2018 Q2 | -5.83 Million USD | -100.0% |
| 2018 Q1 | -2.91 Million USD | 75.51% |
| 2018 FY | -17.8 Million USD | -13.09% |
| 2018 Q3 | -4.06 Million USD | 30.4% |
| 2017 FY | -15.74 Million USD | -44.6% |
| 2017 Q4 | -11.92 Million USD | -300.27% |
| 2017 Q3 | -2.97 Million USD | 27.22% |
| 2017 Q2 | -4.09 Million USD | -226.22% |
| 2017 Q1 | 3.24 Million USD | 161.89% |
| 2016 FY | -10.88 Million USD | -52.44% |
| 2016 Q1 | -1.18 Million USD | 28.89% |
| 2016 Q2 | -2.71 Million USD | -128.68% |
| 2016 Q3 | -1.74 Million USD | 35.97% |
| 2016 Q4 | -5.23 Million USD | -200.86% |
| 2015 Q4 | -1.67 Million USD | 8.58% |
| 2015 Q2 | -2 Million USD | -22.34% |
| 2015 Q1 | -1.63 Million USD | 54.01% |
| 2015 FY | -7.14 Million USD | 44.54% |
| 2015 Q3 | -1.82 Million USD | 8.73% |
| 2014 Q3 | -3.07 Million USD | 5.44% |
| 2014 Q4 | -3.56 Million USD | -15.76% |
| 2014 Q2 | -3.25 Million USD | -9.05% |
| 2014 Q1 | -2.98 Million USD | -5674.96% |
| 2014 FY | -12.87 Million USD | 7.57% |
| 2013 Q1 | -5.22 Million USD | -338.38% |
| 2013 Q2 | -5.28 Million USD | -1.14% |
| 2013 Q4 | 53.52 Thousand USD | 101.54% |
| 2013 Q3 | -3.47 Million USD | 34.32% |
| 2013 FY | -13.93 Million USD | -144.99% |
| 2012 Q2 | -867.23 Thousand USD | -51.91% |
| 2012 Q4 | -1.19 Million USD | 60.99% |
| 2012 FY | -5.68 Million USD | 0.0% |
| 2012 Q1 | -570.88 Thousand USD | 0.0% |
| 2012 Q3 | -3.05 Million USD | -252.4% |
| 2001 Q2 | -17.76 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 74.439% |
| Prenetics Global Limited | -62.72 Million USD | 5.256% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -3738.953% |
| CareDx, Inc | -190.28 Million USD | 68.769% |
| Exact Sciences Corporation | -204.14 Million USD | 70.89% |
| Exagen Inc. | -23.68 Million USD | -150.863% |
| Inotiv, Inc. | -105.14 Million USD | 43.478% |
| Guardant Health, Inc. | -479.44 Million USD | 87.605% |
| Biodesix, Inc. | -52.14 Million USD | -13.963% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -2160.404% |
| Precipio, Inc. | -5.85 Million USD | -915.325% |
| iSpecimen Inc. | -11.09 Million USD | -435.403% |
| Natera, Inc. | -434.8 Million USD | 86.332% |
| Aspira Women's Health Inc. | -16.69 Million USD | -256.064% |
| Standard BioTools Inc. | -74.65 Million USD | 20.399% |
| 23andMe Holding Co. | -666.7 Million USD | 91.086% |
| Castle Biosciences, Inc. | -57.46 Million USD | -3.412% |
| Personalis, Inc. | -108.29 Million USD | 45.125% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 32.836% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -497.433% |
| OpGen, Inc. | -32.66 Million USD | -81.909% |
| T2 Biosystems, Inc. | -50.07 Million USD | -18.671% |
| Myriad Genetics, Inc. | -112 Million USD | 46.94% |
| ICON Public Limited Company | 612.33 Million USD | 109.705% |
| NeoGenomics, Inc. | -87.96 Million USD | 32.445% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -3738.953% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 107.032% |
| RadNet, Inc. | 3.04 Million USD | 2052.267% |
| MDxHealth SA | -43.1 Million USD | -37.882% |
| Psychemedics Corporation | -4.15 Million USD | -1330.597% |
| Illumina, Inc. | -1.16 Billion USD | 94.881% |
| Check-Cap Ltd. | -17.56 Million USD | -238.268% |
| Twist Bioscience Corporation | -208.72 Million USD | 71.529% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 64.59% |
| Sera Prognostics, Inc. | -36.24 Million USD | -63.973% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -490.711% |
| OPKO Health, Inc. | -188.86 Million USD | 68.534% |
| Medpace Holdings, Inc. | 282.81 Million USD | 121.013% |
| Neogen Corporation | -9.42 Million USD | -530.793% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -485.098% |
| Prenetics Global Limited | -62.72 Million USD | 5.256% |
| Mainz Biomed B.V. | -26.29 Million USD | -125.995% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -648.733% |
| Trinity Biotech plc | -24.01 Million USD | -147.427% |
| Neuronetics, Inc. | -30.18 Million USD | -96.85% |
| Sotera Health Company | 51.37 Million USD | 215.671% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -648.733% |